Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct 21;20(39):14237-45.
doi: 10.3748/wjg.v20.i39.14237.

Improving outcomes in pancreatic cancer: key points in perioperative management

Affiliations
Review

Improving outcomes in pancreatic cancer: key points in perioperative management

José M Alamo et al. World J Gastroenterol. .

Abstract

This review focused in the perioperative management of patients with pancreatic cancer in order to improve the outcome of the disease. We consider that the most controversial points in pancreatic cancer management are jaundice management, vascular resection and neo-adjuvant therapy. Preoperative biliary drainage is recommended only in patients with severe jaundice, as it can lead to infectious cholangitis, pancreatitis and delay in resection, which can lead to tumor progression. The development of a phase III clinical trial is mandatory to clarify the role of neo-adjuvant radiochemotherapy in pancreatic adenocarcinoma. Venous resection does not adversely affect postoperative mortality and morbidity, therefore, the need for venous resection should not be a contraindication to surgical resection in selected patients. The data on arterial resection alone, or combined with vascular resection at the time of pancreatectomy are more heterogeneous, thus, patient age and comorbidity should be evaluated before a decision on operability is made. In patients undergoing R0 resection, arterial resection can also be performed.

Keywords: Neo-adjuvant therapy; Obstructive jaundice; Pancreatic cancer; Preoperative drainage; Vascular resection.

PubMed Disclaimer

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed
    1. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267. - PMC - PubMed
    1. Saif MW. Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP. 2007;8:545–552. - PubMed
    1. Padillo FJ, Andicoberry B, Muntane J, Lozano JM, Miño G, Sitges-Serra A, Solorzano G, Pera-Madrazo C. Cytokines and acute-phase response markers derangements in patients with obstructive jaundice. Hepatogastroenterology. 2001;48:378–381. - PubMed
    1. Padillo FJ, Andicoberry B, Muntane J, Lozano JM, Miño G, Sitges-Serra A, Pera-Madrazo C. Factors predicting nutritional derangements in patients with obstructive jaundice: multivariate analysis. World J Surg. 2001;25:413–418. - PubMed

MeSH terms